Published in final edited form as:

Addiction. 2017 December ; 112(12): 2227–2236. doi:10.1111/add.13913.

Accuracy of Self-Reported Smoking Abstinence in Clinical Trials of Hospital-Initiated Smoking Interventions

Taneisha S. Scheuermann¹, Kimber P. Richter¹, Nancy A. Rigotti², Sharon E. Cummins³, Kathleen F. Harrington⁴, Scott E. Sherman⁵, Shu-Hong Zhu³, Hilary A. Tindle⁶, Kristopher J. Preacher⁷, and the Consortium of Hospitals Advancing Research on Tobacco (CHART)

¹Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, KS, USA

²Tobacco Research and Treatment Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

³Department of Family Medicine and Public Health, and Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA

⁴Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

⁵Division of General Internal Medicine, New York University School of Medicine, New York, NY, USA

⁶Vanderbilt Center for Tobacco, Addictions, and Lifestyle, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

⁷Department of Psychology & Human Development, Vanderbilt University, Nashville, TN, USA

Abstract

Aims—To estimate the prevalence and predictors of failure biochemically to verify self-reported abstinence among participants enrolled in trials of hospital-initiated smoking cessation interventions.

Design—Comparison of characteristics between participants who verified and those who failed to verify self-reported abstinence.

Settings—Multi-site randomized clinical trials conducted between 2010 and 2014 in hospitals across the United States.

Participants—Recently hospitalized smokers who reported tobacco abstinence 6 months post-randomization and provided a saliva sample for verification purposes (n=822).

Corresponding author: Taneisha S. Scheuermann, PhD, MPH, Department of Preventive Medicine and Public Health, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160. Telephone: (913) 588-2641; Fax: (913) 588-2780; tscheuermann@kumc.edu.

Declaration of Interests: KPR has received clinical trial medications from Nicovum. NAR has been an unpaid consultant for Pfizer and receives royalties from UpToDate.

Clinical Trial Registration: [ClinicalTrials.gov](https://clinicaltrials.gov) NCT01177176 (NAR), NCT01277250 (KFH), NCT01289275 (SHZ), NCT01305928 (KPR), and NCT01363245 (SES).

Measurements—Outcomes were salivary cotinine-verified smoking abstinence at 10ng/ml and 15ng/ml cut points. Predictors and correlates included participant demographics and tobacco use; hospital diagnoses and treatment; and study characteristics collected via surveys and electronic medical records.

Findings—Usable samples were returned by 69.8% of the 1,178 trial participants who reported 7-day point prevalence abstinence. The proportion of participants verified as quit was 57.8% (95% CI 54.4, 60.4; 10 ng/ml cut-off) or 60.6% (95% CI 57.2, 63.9; 15ng/ml). Factors independently associated with verification at 10ng/ml were education beyond high school education (OR=1.51; 95% CI 1.07, 2.11), continuous abstinence since hospitalization (OR=2.82; 95% CI 2.02, 3.94), mailed vs. in-person sample (OR=3.20; 95% CI 1.96, 5.21), and race. African American participants were less likely to verify abstinence than White participants (OR= 0.64; 95% CI 0.44, 0.93). Findings were similar for verification at 15ng/ml. Verification rates did not differ by treatment group.

Conclusions—In the USA, high rates (40%) of hospitalized smokers enrolled in smoking cessation trials fail biochemical verification of their self-reported abstinence.

Keywords

Self-report; Biochemical Verification; Smoking Cessation

Introduction

Assessing smoking abstinence is a challenge for smoking cessation trials [1, 2]. Self-reported abstinence is a simple and convenient method but, participants do not always accurately report their smoking status [3]. As a result, biochemical measures of tobacco use are considered the gold standard for outcomes in clinical trials. Biochemical measures may be more accurate in assessing tobacco use but this advantage must be weighed against their costs and limitations.

Biochemical verification may not be necessary for determining the prevalence of tobacco use in the general population. Population-based epidemiological studies suggest that rates of failed biochemical verification of non-smoking status are low, with country estimates ranging from approximately 1% in the United States to 4% in Poland [4-6]. While these general population studies suggest that misreporting is low, specific subgroups may be more likely to fail verification. Studies have found higher rates of misreporting among individuals in clinical situations where tobacco use is especially stigmatized such as pregnant women [7], patients with cardiac disease [8], and patients with respiratory illness [9].

Likewise, verification may not always be necessary in determining the outcomes of smoking cessation trials—in which investigators are trying to determine the relative effectiveness of different treatments. The SRNT Subcommittee on Biochemical Verification conducted a meta-analysis and found that, using a complete-case approach, only 12.9% of outcome comparisons showed that treatment outcome was affected by biochemical verification [10]. Findings were similar for intent-to-treat analyses. Where discrepancies occurred, significant effects were typically found using self-report, but not found using biochemical verification.

There were two exceptions where biochemical verification yielded a significant treatment effect when self-report did not—these two studies occurred among pregnant smokers. These findings show that differences between self-reported outcomes and biochemically verified outcomes can cause investigators to either falsely reject or fail to reject the null hypothesis.

Several study characteristics may enhance the need for biochemical verification. To help researchers determine when verification might be necessary, the SRNT subcommittee identified three overarching factors that should be considered: (1) demand characteristics, (2) type of population, and (3) type of study [10]. Varying levels of contact with study staff across treatment arms may create a demand bias that could cause smokers in intervention arms to misreport abstinence at a higher rate. The type of population can be categorized as the general population or specific groups such as medical patients, with special groups often experiencing heightened perceived pressures to quit smoking that increase the likelihood of misreporting [8]. Due to one or more of these factors, biochemical verification of smoking abstinence may be needed in randomized trials testing the effectiveness of cessation interventions.

While several studies have investigated the accuracy of self-reported smoking status compared to biomarkers for tobacco use [3, 11], there is little empirical evidence regarding population and study characteristics associated with discrepancies between self-report and validated abstinence in clinical trials. Factors such as education, age, race/ethnicity, diagnosis, number of smokers in the household, even inadvertent exposure to carbon monoxide have been associated with the failure of self-report to match biochemical measures [4, 8, 12]. These studies indicate that demographic and health status characteristics are important in understanding verification failures. However, important gaps remain in the understanding of the degree to which intervention intensity, health status, and other patient characteristics contribute to failed verification—especially in the context of clinical trials.

This study used data from a set of smoking cessation intervention trials with hospitalized smokers to address the gaps in the discourse on verification of smoking status. These National Institutes of Health (NIH)-funded randomized controlled trials comprise the Consortium of Hospitals Advancing Research on Tobacco (CHART). CHART was formed with the goal of conducting translational research on effective smoking cessation interventions initiated during in-patient hospital stays and continuing post-discharge [13].

The aims of this study were to (1) estimate the prevalence of failed verification of self-reported abstinence in clinical trials; (2) estimate the extent to which participant demographics, study characteristics (e.g., sample collection methods), and population factors (e.g., diagnoses provided during hospitalization) are associated with verification of smoking abstinence; and (3) estimate rates of self-reported relapse, other tobacco/nicotine exposures, and verification based on surveys included in sample collection kits.

Methods

Design

The design is a cross-sectional descriptive study comparing the characteristics of participants who verified and those who failed to verify self-reported abstinence. Five of the eight CHART trials participated in this substudy. CHART was jointly funded by the National Heart, Lung, and Blood Institute; National Cancer Institute; National Institute on Drug Abuse; and NIH Office of Behavioral and Social Science Research. CHART researchers collaboratively created a set of core baseline measures and follow-up assessments. CHART trials used similar eligibility criteria. Each trial compared a post-discharge intervention to usual care. The interventions included a web-based program [14], interactive voice-response (IVR) support [15], staff-provided counseling [16], quitline counseling [17, 18], and provision of nicotine patches [18].

Participants were enrolled during their hospital stay, provided informed consent and baseline data before being randomly assigned to treatment arm. Trials conducted in Birmingham, Alabama [14]; Boston, Massachusetts [15]; Kansas City, Kansas [17]; New York, New York [16]; and San Diego and Davis, California [18] used salivary cotinine to biochemically verify self-reported smoking abstinence at 6-months after randomization using a shared protocol. This shared protocol was designed to yield high return rates and collect comparable data for pooled analyses. Institutional Review Boards at each study site approved all study procedures and permitted de-identified data to be shared across CHART.

Participants

Participants in the CHART studies who self-reported 7-day point prevalence tobacco abstinence at 6 month post-randomization follow-up were asked to provide a saliva sample. Participants were ineligible for cotinine verification if they self-reported current use of other forms of tobacco, electronic cigarettes (e-cigarettes), or NRT. One trial conducted its own study on the effects of high (\$100) versus low (\$20) reimbursement for returning saliva kits [18]; participants reporting 7-day abstinence at 6 months were randomized to one of the two reimbursement conditions. Only participants receiving high reimbursement (consistent with the range of reimbursement of other CHART studies) were included in the current analyses. A second trial collected saliva samples only during a 14 month period of their trial; no samples were collected for the remainder of the study [16].

Procedures

Participants completed the 6-month follow-up survey via telephone, reported their smoking status, and were screened for eligibility for cotinine verification. Participants who self-reported 7-day abstinence and were otherwise eligible were either mailed kits containing self-addressed, prepaid return envelopes with instructions to provide a saliva sample or asked to provide a saliva sample in person. Two of the five studies collected samples via mail only; three studies collected samples via mail and in-person. Two studies invited individuals who lived within the local area to attend the clinic, meet at a public place, or schedule a home visit to provide a saliva sample. The third study that collected in-person

samples did so among a small number of participants who were rehospitalized during the sample collection window.

Reimbursement for returning a sample ranged from \$50 (one study) to \$100 (four studies). One of the studies reimbursed participants \$100 for in-person samples and \$75 for mailed samples. Participants were generally reimbursed by check or gift card. To ensure high return rates, the protocol was to make up to five attempts via phone and/or mailed reminders to obtain saliva samples. Only samples returned within 30 days of the 6-month survey date were analyzed.

Saliva samples were collected via self-administered oral swabs which were then enclosed in protective tubes for storage and shipping. Samples were stored in a standard freezer and mailed in batches for analysis at Salimetrics. Salivary cotinine was analyzed by enzyme immunoassay (EIA), which has a limit of quantification of 0.15ng/ml and produces results comparable to gas chromatography/mass spectroscopy [19, 20] and liquid chromatography/mass spectroscopy [21] but may yield more false negatives [21].

Three of the five projects included a brief survey in the mailed kit that asked about past 7-day tobacco or nicotine product use, and secondhand smoke exposure in the 24 hours before sample collection. A fourth project included a survey in the mailed kit that assessed past 7-day smoking among the last 40 participants who were eligible for cotinine verification. These surveys were returned to the researchers along with the saliva sample.

Measures

Predictors—Baseline variables included age, gender, race, ethnicity and education. At 6-month follow-up, participants reported whether they lived with another smoker, whether they smoked at all since hospital discharge, and whether they had smoked in the previous 7 days (point prevalence abstinence).

Information for the hospital stay during which participants were enrolled was extracted from each participant's electronic medical record: primary and secondary discharge diagnoses, whether admission was through the emergency department, and insurance status. Diagnoses were categorized using ICD-9 codes for neoplasms, respiratory diseases, cardiovascular diseases, and mental health disorders. Primary discharge diagnosis codes for neoplasms, respiratory diseases, and cardiovascular diseases were combined to indicate smoking-related diseases. Detailed descriptions of the core measures are provided elsewhere [13].

Outcomes—Two cut-points were used for cotinine verification of self-report: 10ng/ml, a widely adopted threshold for active smoking in recent smoking cessation clinical trials [22-24] and the higher cut-point of 15ng/ml recommended by the SRNT Subcommittee on Biochemical Verification [10]. Although lower cut-points have been recommended based on population data [25], we retained higher cut-points because ex-smokers may be exposed to more environmental tobacco smoke than nonsmokers in the general population [26]. The two cut-points were used to create dichotomous variables for verification (1 = cotinine verified, 0 = failed verification).

Statistical Analyses

Descriptive statistics were computed for participant characteristics. Logistic regressions were used to compare participant characteristics between those who were eligible and returned a usable sample and participants who were eligible who did not return a usable sample. We calculated the proportion of participants whose self-reported smoking abstinence was verified using the 10ng/ml and 15ng/ml cut-points.

In order to identify predictors of verification of smoking abstinence in the study sample, we used logistic regressions to determine differences between participants who were verified as abstinent vs. failed verification. Comparisons were made on: demographic characteristics, Medicaid insurance status, discharge diagnoses, whether the participant smoked since hospital discharge, and study-related characteristics. We tested multivariable logistic regressions to examine the associations of the demographic, insurance, smoking-status, and study-related characteristics on verification of abstinence using 10ng/ml and 15ng/ml cut-points. In a preliminary analysis, we included study site as a random effect in logistic regression models to allow for possible heterogeneity of effect across study sites. These effects were negligible and non-significant and hence were dropped as a model component.

Using data from the subset of participants who completed the survey mailed with the saliva kit, we calculated the proportions of participants who reported (1) smoking in the past 7 days, (2) other tobacco use (e-cigarettes were included in this category), (3) nicotine replacement therapy use, and (4) past 24-hour second hand smoke exposure. As a sub-analysis, we estimated verification rates of participants who reported past-24 hour secondhand smoke exposure and rates of those reporting none. All analyses were conducted in SPSS 23.0.

Results

Figure 1 presents the flow diagram for participants in this study. In the five participating trials, 4,206 participants completed the 6-month survey. Of these, 1,708 reported 7-day abstinence but 530 were ineligible for the study. The sample size was further reduced by 36 refusals, 219 samples not returned, 15 with insufficient amounts of saliva, and 86 samples returned more than 30 days after completion of the 6 month survey. This resulted in a final sample of 822, 70% of participants who were eligible for cotinine verification. Samples were collected via mail ($n = 670$) and in-person ($n = 152$). Mailed samples were received an average of 14.5 days (standard deviation [SD] = 6.8) after the 6 month survey and the mean for in-person collection was 8.7 days (SD = 8.8).

Descriptive statistics for eligible participants who returned usable samples vs. who did not return a sample are presented in Table 1. The majority were White (56.1%) and 32.6% were African American. American Indian (1.7%), Asian/Pacific Islander (1.2%), and multiracial (3.5%), were combined for analytic purposes into “Other race” (4.9%). There were few differences between eligible participants who returned usable samples ($n=822$) versus those who did not ($n=356$); higher proportions of African Americans and participants with primary discharge diagnoses of cardiovascular or respiratory diseases returned usable samples (see Table 1). Figure 2 presents the distribution of cotinine values in the sample, 5%

(n = 41) had cotinine values below 0.15 ng/ml, the limit of sensitivity. Based on the widely used cut-point of 10 ng/ml, 57.8% of participants were verified quit (see Table 2) and using 15ng/ml, 60.6% were verified quit (see supplemental Table 2b).

Table 2 provides participant characteristics (n=822) by cotinine verification status using the 10 ng/ml cut-point. Participants with verified abstinence differed from participants who failed verification on several variables ($p<0.05$). In univariate comparisons, participants who were older, female, White, had more than a high school education, and provided the saliva sample by mail (vs. in person) were more likely to validate self-reported quitting. Participants with Medicaid insurance (vs. other insurance), had a smoking-related primary discharge diagnosis, and were not continuously abstinent since hospital discharge were less likely to verify self-reported quitting. The proportions of participants who verified self-reported abstinence also differed by study site. Findings were similar using the 15ng/ml cut-point, except that the difference by insurance type was non-significant.

We estimated multivariable logistic regression models using 10 ng/ml and 15ng/ml cut-points, adjusting for study site and including age, gender, race, ethnicity, education, insurance (Medicaid vs. other), admission type (emergency room vs. other), primary discharge diagnoses (smoking-related disease; mental health disorder), secondary mental disorder diagnosis, continuous abstinence since hospital discharge, intervention treatment assignment, sample collection method (mailed vs. in person), and an interaction term between treatment assignment and sample collection method (see Table 3). We included this interaction due to the differences in verification rates by collection method. Using the 10ng/ml cut-point, the treatment assignment by sample collection method interaction was non-significant (AOR 1.34, 95% CI 0.58, 3.13, $p = 0.495$), therefore, we report the model results without this effect. Participants who had education beyond high school, were continuously abstinent since hospitalization, and who mailed their sample were more likely to biochemically verify self-reported abstinence. Compared to White participants, African American participants were less likely to be cotinine-verified quit. The odds of cotinine verification did not differ by treatment arm. The interaction term between treatment assignment and sample collection method was also non-significant in the logistic regression model for cotinine verification at the 15ng/ml cut-point (AOR 1.37, 95% CI 0.58, 3.20, $p = 0.472$) and overall findings were similar to the 10ng/ml model.

Table 4 presents cotinine values (median, interquartile ranges, ranges) and cotinine verification rates for all participants and for subgroups. Among the four study sites that repeated their assessment of past 7-day smoking status at the time of saliva collection (n=653), 168 (25.73%) of those who reported abstinence at 6-month follow-up reported smoking in the 7 days prior to saliva collection. Among the 618 participants in three studies that were asked about other nicotine exposure in the 7-days prior to saliva collection, 43 (7.0%) reported other tobacco or e-cigarette use and 39 (6.3%) reported NRT use; 367 (59.4%) also reported that they had been exposed to indoor secondhand smoke in the past 24 hours.

Discussion

This study examined biochemical verification rates of self-reported smoking abstinence in five smoking cessation randomized clinical trials that enrolled smokers at hospitalization. Among self-reported quitters at 6 month follow-up, analysis of salivary cotinine using the widely accepted cut-point of 10ng/ml yielded a 58% verification rate. Thus, approximately 42% of participants who self-reported abstinence failed verification. We found a bimodal distribution of cotinine values consistent with samples including both non-smokers and active smokers [11, 26, 27]. Two demographic factors (African American race and lower education), one study procedural factor (in-person sample collection) and one quitting experience factor (non-continuous cessation) were significantly associated with a decreased likelihood of verifying self-reported smoking status.

Similar to findings from the parent trials, our results showed that the likelihood of verifying abstinence was not related to treatment group. Each parent trial found that sample return rates and verifications rates were the same across the intervention and control study arms, and that verified abstinence paralleled self-report [14-18]. For the field of tobacco research, this finding raises a key methodological question: *When are the time, costs, and limitations of biochemical verification justified in research trials whose goal is to assess the efficacy of an intervention compared to a control condition?*

Sample collection method was associated with verification rate even after taking into account demographic and smoking-related variables. Three of the five trials included in these analyses also collected in-person samples. The two studies with the highest proportions of in-person samples provided more appealing participant incentives (e.g., cash vs. check) for in-person verification, and this may have increased the likelihood that even participants who relapsed or misreported followed through to provide a sample. Verification rate variation also may have resulted from differences in the study populations due to regional culture, proportion of minorities, population density or other factors that differed between study sites.

Most of the saliva samples in this study were returned via mail. Four trials provided a survey to repeat the self-reported assessment of tobacco use in the mailed kits. We found that one in four of the participants returning this survey with their sample reported smoking in the past 7 days. This suggests that these participants either misreported at the outcome survey or relapsed between the time they completed the survey and received the collection kit. A smaller proportion reported using other tobacco, e-cigarettes, or NRT in the past 7 days. These admissions indicate some discrepant results could potentially occur as a result of relapse to smoking or other nicotine exposure during the interim between reporting smoking status and providing a sample for verification. Participants who denied using tobacco or nicotine products on the mailed survey had a higher rate of cotinine-verified abstinence (77%). Further, participants who indicated that they had not smoked but were exposed to secondhand cigarette smoke in the past 24 hours had lower rates of verification than those who indicated no exposure. Given the range of cotinine values for secondhand smoke exposed participants, many who failed verification in this subset were likely to be active smokers [27].

Race and education were the only demographic variables associated with verification when controlling for other characteristics. Perhaps these differences by race and education reflect a variation in response to the demand characteristics of being in a smoking cessation trial or simply wanting to avoid stigma that may be associated with continued smoking. However, the reasons that these variables impacted verification rates are unclear.

Previous recommendations for smoking cessation trials have included proposals for assessing continuous or prolonged smoking abstinence as the standard outcome [1, 2]. Our analyses showed that controlling for individual and study-level characteristics, participants who reported that they remained abstinent since their hospitalization were more likely to be cotinine-verified abstinent at six month follow-up. The fact that participants with prolonged abstinence have higher verification rates suggests that prolonged abstinence may be a better indicator of long-term smoking cessation success. However, approximately 30% of participants reporting prolonged abstinence failed verification. This suggests that verification has potential utility even for longer time frames.

The current study makes an important contribution to the on-going scientific dialogue regarding biochemical verification of smoking abstinence by including findings from five large clinical trials with hospitalized smokers. Study strengths include using data from several regions within the United States and from a variety of hospitals. Study sites collaborated at the beginning of the trials to ensure standard sample collection and processing procedures. However, there are several limitations. Saliva samples were analyzed using EIA methods rather than the better performing liquid or gas chromatographic methods [19, 21]. However, the range and distribution of cotinine values appears similar to data from population-based studies using chromatographic assays methods [25, 26]. We were unable to determine whether the reason for failed verification was due solely to misreporting or excessive secondhand smoke exposure. Sample collection was not directly observed for mailed samples. The return rate of 70% for usable saliva samples is consistent with evaluations from population-based, low-intensity trials [28], however, the fact that 30% of participants did not have samples available for verification remains a limitation.

In conclusion, across 5 large clinical trials of smoking cessation interventions, only about 60% of participants reporting not smoking validated that self-report with cotinine levels consistent with smoking abstinence. This underscores that self-report measures are likely to result in inflated smoking cessation rates within this population. Further, when collecting mailed samples for cotinine testing, researchers should explore the utility of including a survey to reduce discrepancies in self-report. Future studies that explore reasons for discrepant reporting and how this source of error can be minimized are also warranted.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The Consortium of Hospitals Advancing Research on Tobacco (CHART) was funded by the National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA) and the

Office of Behavioral and Social Sciences (OBSSR) by cooperative agreements to a research coordinating unit (Kaiser Foundation Research Institute, PI: Victor Stevens, PhD, U01HL52333) and six research projects (New York University School of Medicine, PI: Scott Sherman, MD, U01HL105229; University of California San Diego, PI: Shu-Hong Zhu, PhD, U01CA 159533; University of Kansas Medical Center, PI: Kimber Richter, PhD, U01HL105232; University of Alabama Birmingham, PI: William Bailey, MD, U01DA031515; University of Michigan Ann Arbor, PI: Sonia Duffy, PhD, U01HL105218; Kaiser Foundation Research Institute, PI: Jeffrey Fellows, PhD, U01HL105231). An additional project (Massachusetts General Hospital, PI: Nancy Rigotti, MD, Co-I: Hilary Tindle, MD, MPH, RC1HL099668) has been included in the consortium. NIH Project Scientists on this project have included Lawton Cooper, MD, Sarah Duffy, PhD, Debra Grossman, PhD, Glen Morgan, PhD, William Riley, PhD, Catherine (Kate) Stoney, PhD, and Xin Tian, PhD. We would like to thank the hospital and research staff who contributed to the development and implementation of these trials and the patients who participated.

Funding: This work was supported by National Institutes of Health (NIH) grants RC1HL099668 (NAR), U01DA031515 (KFH), U01CA159533 (SHZ), U01HL105232 (KPR), and U01HL105229 (SES).

References

1. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. *Nicotine Tob Res.* 2003; 5:13–26. [PubMed: 12745503]
2. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. *Addiction.* 2005; 100:299–303. [PubMed: 15733243]
3. Conner Gorber S, Schofield-Hurwitz S, Hardt J, Levasseur G, Tremblay M. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. *Nicotine Tob Res.* 2009; 11:12–24. [PubMed: 19246437]
4. Caraballo RS, Giovino GA, Pechacek TF, Mowery PD. Factors Associated with Discrepancies between Self-Reports on Cigarette Smoking and Measured Serum Cotinine Levels among Persons Aged 17 Years or Older: Third National Health and Nutrition Examination Survey, 1988–1994. *Am J Epidemiol.* 2001; 153:807–814. [PubMed: 11296155]
5. West R, Zatonski W, Przewozniak K, Jarvis MJ. Can We Trust National Smoking Prevalence Figures? Discrepancies Between Biochemically Assessed and Self-Reported Smoking Rates in Three Countries. *Cancer Epidemiol Biomarkers Prev.* 2007; 16:820–822. [PubMed: 17416777]
6. Yeager DS, Krosnick JA. The Validity of Self-Reported Nicotine Product Use in the 2001–2008 National Health and Nutrition Examination Survey. *Med Care.* 2010; 48:1128–1132. [PubMed: 20940652]
7. Dietz PM, Homa D, England LJ, Burley K, Tong VT, Dube SR, et al. Estimates of nondisclosure of cigarette smoking among pregnant and nonpregnant women of reproductive age in the United States. *Am J Epidemiol.* 2011; 173:355–359. [PubMed: 21178103]
8. Pell JP, Haw SJ, Cobbe SM, Newby DE, Pell AC, Oldroyd KG, et al. Validity of self-reported smoking status: Comparison of patients admitted to hospital with acute coronary syndrome and the general population. *Nicotine Tob Res.* 2008; 10:861–866. [PubMed: 18569760]
9. Lewis SJ, Cherry NM, McI Niven R, Barber PV, Wilde K, Povey AC. Cotinine levels and self-reported smoking status in patients attending a bronchoscopy clinic. *Biomarkers.* 2003; 8:218–228. [PubMed: 12944174]
10. Srnt Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. *Nicotine Tob Res.* 2002; 4:149–159. [PubMed: 12028847]
11. Kim S. Overview of Cotinine Cutoff Values for Smoking Status Classification. *Int J Environ Res Public Health.* 2016; 13:1236.
12. Aurrekoetxea JJ, Murcia M, Rebagliato M, Lopez MJ, Castilla AM, Santa-Marina L, et al. Determinants of self-reported smoking and misclassification during pregnancy, and analysis of optimal cut-off points for urinary cotinine: a cross-sectional study. *BMJ open.* 2013;3.
13. Riley WT, Stevens VJ, Zhu SH, Morgan G, Grossman D. Overview of the Consortium of Hospitals Advancing Research on Tobacco (CHART). *Trials.* 2012; 13:122. [PubMed: 22852768]
14. Harrington KF, Kim YI, Chen M, Ramachandran R, Pisu M, Sadasivam RS, et al. Web-based intervention for transitioning smokers from inpatient to outpatient care: an RCT. *Am J Prev Med.* 2016; 51:620–629. [PubMed: 27647062]

15. Rigotti NA, Regan S, Levy DE, Japuntich S, Chang Y, Park ER, et al. Effect of a sustained care intervention on post-discharge smoking cessation among hospitalized adults: a randomized clinical trial. *JAMA*. 2014; 312:719–728. [PubMed: 25138333]
16. Sherman SE, Link AR, Rogers ES, Krebs P, Ladapo JA, Shelley DR, et al. Smoking-Cessation Interventions for Urban Hospital Patients: A Randomized Comparative Effectiveness Trial. *Am J Prev Med*. 2016; 51:566–577. [PubMed: 27647057]
17. Richter KP, Faseru B, Shireman TI, Mussulman LM, Nazir N, Bush T, et al. Warm Handoff Versus Fax Referral for Linking Hospitalized Smokers to Quitlines. *Am J Prev Med*. 2016; 51:587–596. [PubMed: 27647059]
18. Cummins SE, Gamst AC, Brandstein K, Seymann GB, Klonoff-Cohen H, Kirby CA, et al. Helping hospitalized smokers: a factorial RCT of nicotine patches and counseling. *Am J Prev Med*. 2016; 51:578–586. [PubMed: 27647058]
19. Alterman AI, Gariti P, Niedbala RS. Varying results for immunoassay screening kits for cotinine level. *Psychol Addict Behav*. 2002; 16:256–259. [PubMed: 12236461]
20. Salimetrics. State College, PA: 2015. High Sensitivity Salivary Cotinine Quantitative Enzyme Immunoassay Kit. <https://www.salimetrics.com/assets/documents/1-2002n.pdf> (Archived by WebCite® at <http://www.webcitation.org/6p8f14ePY> on March 21, 2017)
21. Kauffman RM, Ferketich AK, Murray DM, Bellair PE, Wewers ME. Measuring tobacco use in a prison population. *Nicotine Tob Res*. 2010; 12:582–588. [PubMed: 20395359]
22. Etter JF. Financial incentives for smoking cessation in low-income smokers: study protocol for a randomized controlled trial. *Trials*. 2012; 13:88. [PubMed: 22721577]
23. Cooper S, Foster K, Naughton F, Leonardi-Bee J, Sutton S, Ussher M, et al. Pilot study to evaluate a tailored text message intervention for pregnant smokers (MiQuit): study protocol for a randomised controlled trial. *Trials*. 2015; 16:29. [PubMed: 25622639]
24. Cheung YTD, Leung JPK, Cheung CKC, Li WHC, Wang MP, Lam TH. Motivating smokers at outdoor public smoking hotspots to have a quit attempt with a nicotine replacement therapy sample: study protocol for a randomized controlled trial. *Trials*. 2016; 17:355. [PubMed: 27456342]
25. Benowitz NL, Bernert JT, Caraballo RS, Holiday DB, Wang J. Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. *Am J Epidemiol*. 2009; 169:236–248. [PubMed: 19019851]
26. Jarvis MJ, Fidler J, Mindell J, Feyerabend C, West R. Assessing smoking status in children, adolescents and adults: cotinine cut-points revisited. *Addiction*. 2008; 103:1553–1561. [PubMed: 18783507]
27. Goniewicz ML, Eisner MD, Lazcano-Ponce E, Zielinska-Danch W, Koszowski B, Sobczak A, et al. Comparison of Urine Cotinine and the Tobacco-Specific Nitrosamine Metabolite 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol (NNAL) and Their Ratio to Discriminate Active From Passive Smoking. *Nicotine Tob Res*. 2011; 13:202–208. [PubMed: 21330276]
28. Glasgow RE, Mullooly JP, Vogt TM, Stevens VJ, Lichtenstein E, Hollis JF, et al. Biochemical validation of smoking status: Proscons, and data from four low-intensity intervention trials. *Addict Behav*. 1993; 18:511–527. [PubMed: 8310871]

Figure 1. Flow Diagram for Cotinine Verification Study

Figure 2. Distribution of Cotinine Values among Self-Reported Quitters (n = 822)

Table 1
Baseline Characteristics of Participants Eligible for Biochemical Verification by Sample Status

	Returned Usable Sample (n = 822)	Did Not Return Usable Sample (n=356)	P value
	<i>% or Mean (SD)</i>		
Age			0.595
18-44 years, %	35.7%	33.4%	
45-64 years, %	52.7%	55.9%	
65 years, %	11.6%	10.7%	
Male, %	56.4%	54.4%	0.537
Education > High School, %	44.0%	47.2%	0.320
Race			0.045
White, %	56.1%	63.2%	
African American/Black, %	32.6%	25.6%	
Other, %	11.3%	11.2%	
Ethnicity			
Latino, %	11.9%	14.0%	0.313
Primary Discharge Diagnosis			
Cardiovascular diseases, %	15.7%	9.6%	0.005
Respiratory diseases, %	4.9%	1.1%	0.002
Neoplasms, %	0.9%	1.1%	0.656
Mental Health Disorders, %	1.5%	0.8%	0.386
Secondary Diagnosis			
Mental Health Disorder, %	45.6%	31.2%	<0.001
Cigarettes per day, mean (SD)	13.54 (10.82)	12.76 (8.83)	0.229
Daily Smoking (≥ 25 days/month, %)	74.1%	77.2%	0.658
Past 30 day other tobacco use, %	7.4%	6.9%	0.773
Treatment Intervention Group, %	53.4%	57.3%	0.218

Table 2
Verification Rates at 10ng/mL by Participant and Study Characteristics, Univariate Analyses (n = 822)

	n	% Verified Abstinent	95% CI	P Value
<i>All participants</i>	822	57.8%	54.4, 61.2	
Age				0.002
18-44 years	147	50.2%	44.4, 55.9	
45-64 years	263	60.9%	56.3, 65.5	
65 years	64	67.4%	57.9, 76.8	
Gender				0.025
Female	222	62.4%	57.3, 67.4	
Male	251	54.6%	50.0, 59.1	
Race				<0.001
White	299	64.9%	60.5, 69.2	
African American	123	45.9%	39.9, 51.9	
Other	53	57.0%	46.9, 67.1	
Ethnicity				
Latino	56	57.1%	47.3, 67.0	0.891
Education				0.020
High School	249	54.2%	49.7, 58.8	
> High School	225	62.3%	57.3, 67.3	
Primary Insurance				0.026
Medicaid	107	52.7%	45.8, 59.6	
Other Insurance	342	61.7%	57.7, 65.8	
Admission through emergency room	284	56.1%	51.8, 60.5	0.102
Live with Smoker at 6 month follow-up	137	55.9%	49.7, 62.1	0.880
Any of Smoking Disease groups-Primary Diagnosis	115	65.3%	58.3, 72.4	0.022
Mental Health Disorder-Primary Diagnosis	7	58.3%	30.4, 86.3	0.969
Mental Health Disorder-Secondary Diagnosis	211	56.3%	51.2, 61.3	0.419
Abstinent Since Hospital Discharge	325	68.3%	64.1, 72.5	<0.001
Treatment Arm Assignment				0.923
Intervention Arm	253	57.6%	53.0, 62.3	
Control Arm	222	58.0%	53.0, 62.9	
Saliva Collection Method				<0.001
In Person	49	32.2%	24.8, 39.7	
Mailed	426	63.6%	59.9, 67.2	
Study Site				<0.001
New York	71	50.7%	42.4, 59.0	
Alabama	128	48.9%	42.8, 54.9	
California	30	42.3%	30.7, 53.8	
Kansas	193	67.0%	61.6, 72.5	
Massachusetts	53	86.9%	78.4, 95.4	

Table 3
Results from Logistic Regression Models for Cotinine-Verified Self-Reported Abstinence

	10ng/mL Cotinine			15ng/mL Cotinine		
	Odds Ratio	95% CI	P value	Odds Ratio	95% CI	P value
Age						
45-64 years vs. 18-44 years	1.09	0.57, 2.08	0.797	0.74	0.37, 1.48	0.392
65 years vs. 18-44 years	1.34	0.74, 2.42	0.336	0.97	0.51, 1.84	0.914
Gender						
Female vs. Male	1.24	0.88, 1.73	0.218	1.31	0.93, 1.86	0.123
Race						
African American vs. White	0.64	0.44, 0.93	0.019	0.59	0.41, 0.87	0.007
Other Race vs. White	0.75	0.40, 1.40	0.374	0.76	0.40, 1.45	0.404
Latino	1.23	0.65, 2.32	0.524	1.14	0.59, 2.19	0.696
Education						
> High School vs High School	1.51	1.07, 2.11	0.018	1.71	1.20, 2.43	0.003
Insurance						
Medicaid vs. Other	0.85	0.58, 1.25	0.420	1.03	0.70, 1.52	0.881
Admission Through Emergency Room vs. Other Admission	0.82	0.56, 1.19	0.288	0.90	0.62, 1.32	0.601
Any of Smoking Disease groups-Primary Diagnosis	1.11	0.72, 1.70	0.643	1.14	0.73, 1.79	0.557
Mental Health Disorder-Primary Diagnosis	1.09	0.30, 4.02	0.897	1.53	0.38, 6.13	0.548
Mental Health Disorder-Secondary Diagnosis	0.94	0.62, 1.42	0.766	0.96	0.63, 1.47	0.849
Continuous Abstinence since Hospital Discharge	2.82	2.02, 3.94	<0.001	3.28	2.32, 4.64	<0.001
Treatment Arm						
Intervention vs. Control	1.14	0.82, 1.58	0.440	1.13	0.81, 1.59	0.474
Saliva Collection Methods						
Mailed vs. In Person	3.20	1.96, 5.21	<0.001	3.35	2.04, 5.50	<0.001

Note. Logistic regressions adjusted for study site. Due to missing data, analyses were conducted on 750 participants. Statistically significant odds ratios are in bold face.

Table 4
Cotinine Verification Status among Participants Reporting 7-Day Point Prevalence Abstinence at 6 Month Follow-up

Sample Size		Cotinine Value (ng/mL)		Cotinine Verified (10ng/mL)		Cotinine Verified (15ng/mL)	
n	Median	Interquartile Range	Range	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
822	4.7	185	0 - 1561	57.8% (54.4, 61.2)		60.6% (57.2, 63.9)	
<i>Subset who returned survey to report on their tobacco use status with saliva sample (n = 618)</i>							
All respondents	618	5.3	183	0 - 1561	56.5% (52.6, 60.4)	59.2% (55.3, 63.1)	
Report 7-day abstinence from tobacco and NRT	435	2.4	7	0 - 1558	77.2% (73.3, 81.2)	81.1% (77.5, 84.8)	
Report 7-day use of tobacco or NRT	183	320.1	400	0 - 1561	7.1% (3.4, 10.8)	7.1% (3.4, 10.8)	
<i>Subset with a completed survey at sample collection who reported abstinence from tobacco and no nicotine product use in the past 7 days (n = 435)</i>							
No past 24-hr SHS	218	1.5	3	0 - 1083	88.1% (83.8, 92.4)	92.2% (88.6, 95.8)	
Past 24-hr SHS	217	3.8	23	0 - 1558	66.4% (60.0, 72.7)	70.0% (63.9, 76.2)	

Note. Secondhand Smoke (SHS).